Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.55 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.55 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.55 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.55 |
| ▸ | ADK | P55263 | 1/20 | 0.55 |
| ▸ | PRMT5 | O14744 | 13/20 | 0.53 |
| ▸ | WDR77 | Q9BQA1 | 12/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15397029 | 0.90 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL22334075 | 0.90 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL22434784 | 0.90 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL22334076 | 0.90 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL18572642 | 0.88 | PRMT5 (0.56) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL16882801 | 0.88 | PI4KA (0.53) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL15506579 | 0.88 | PI4KA (0.53) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL18572643 | 0.86 | PRMT5 (0.53) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL18571936 | 0.85 | PRMT5 (0.53) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL18572224 | 0.84 | PRMT5 (0.52) | PI4KAPI4K2BPI4K2API4KBADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251390-A1 | 7-DEAZAPURINE MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. | 2016-09-01 | — | — | US | disclosed |
| US-20160251390-A1 | 7-DEAZAPURINE MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. | 2016-09-01 | — | — | US | disclosed |
| US-9145438-B2 | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145438-B2 | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2015-09-29 | — | — | US | disclosed |
| EP-2646454-B1 | 7-DEAZAPURINE MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | EPIZYME INC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-8722877-B2 | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722877-B2 | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20140073597-A1 | 7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073597-A1 | 7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. (US) | 2014-03-13 | — | — | US | disclosed |
| WO-2012075500-A2 | 7-DEAZAPURINE MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073597-A1 | 7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof | TPMT, HNMT, EHMT1 | PI4KA 1952/4885PI4K2B 2232/4885PI4K2A 2346/4885 |
| US-20160251390-A1 | 7-DEAZAPURINE MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | TPMT, HNMT, EHMT1 | PI4KA 1952/4885PI4K2B 2232/4885PI4K2A 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.